Vyvanse® Chewable Tablet added to Ontario Formulary

Vyvanse® (lisdexamfetamine dimesylate) chewable tablet will be publically reimbursed in Ontario for ADHD treatment from March 31, 2020 for individuals (6 years and older) who require 12-hour continuous coverage due to academic and/or psychosocial needs, under these circumstances:

• Patients demonstrate significant and problematic disruptive behaviour or who problems with inattention that interfere with learning; AND
• Medication is prescribed by, or in consultation with, a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD; AND
• Patients have been tried on methylphenidate immediate release (IR) or methylphenidate

Vyvanse® chewable tablets are administered once daily in the morning and are available in six doses: 10 mg, 20 mg, 30 mg, 40 mg, 50 mg and 60 mg.

To learn more about the eligibility criteria for reimbursement of Vyvanse® (lisdexamfetamine dimesylate) chewable tablet in Ontario, please visit:

http://www.health.gov.on.ca/en/pro/programs/drugs/formulary43/summary_edition43_20200324.pdf

Originally published on caddra.ca